UNITED STATES
SECURITY AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934
Date of Event: December 26, 1997
Date of Report: January 9, 1998
NEUROBIOLOGICAL TECHNOLOGIES, INC.
(Exact name of small business issuer as specified in its charter)
Delaware
(State or other jurisdiction of incorporation or organization)
0-23280 94-3049219
(Commission File Number) (IRS Employer Identification No.)
1387 Marina Way South
Richmond, California 94804
(Address of principal executive offices)
(510) 215-8000
(Registrant's telephone number, including area code)
<PAGE>
ITEM 5. Other Events.
Neurobiological Technologies, Inc. has been advised by Nasdaq that the company's
common stock will be moved from The Nasdaq National Market to the Nasdaq
SmallCap Market effective December 26, 1997. The company's common stock will be
listed on the Nasdaq SmallCap Market pursuant to an exception to the initial net
tangible assets requirement and to a waiver to the initial per share bid price
requirement.
While Neurobiological Technologies, Inc. failed to meet the tangible assets
requirements as of June 30, 1997, the company was granted a temporary exception
from this standard subject to Neurobiological Technologies, Inc. meeting certain
conditions. The exception will expire on January 15, 1998. In addition, the
company will be required to meet the $1 per share bid price requirement for
continued listing by January 15, 1998. In the event that the company is deemed
to have met these conditions, it shall continue to be listed on The Nasdaq
SmallCap Market. The company believes that it can meet these conditions,
however, there can be no assurance that it will do so. If at some future date
the company's securities should cease to be listed on The Nasdaq SmallCap
market, they may continue to be listed in the OTC-Bulletin Board.
Effective December 26, 1997, and for the duration of this exception, the
company's Nasdaq symbol will be NTIIC.
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
NEUROBIOLOGICAL TECHNOLOGIES, INC.
January 9, 1998 /s/ Paul E. Freiman
-------------------
Paul E. Freiman
President, Chief Executive Officer
(Principal Executive and Accounting Officer)
and Director
